Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EgaletSTU:EGP Receivables Turnover is 0.67 as of Mar. 2020. The stock has 2 warning signs investors should review.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Egalet's Revenue for the
three
months ended in Mar. 2020 was €17.26 Mil. Egalet's average Accounts Receivable for the
three
months ended in Mar. 2020 was €25.62 Mil.
Hence, Egalet's Receivables Turnover for the
three
months ended in Mar. 2020 was 0.67.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Egalet Receivables Turnover Related Terms
Egalet Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Egalet's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:EGP vs CPHI, TLGT, KGKG: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Egalet's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egalet Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Egalet's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Egalet's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egalet (STU:EGP) has a Receivables Turnover of 0.67 as of Mar. 2020. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Egalet and its competitors.
Is Egalet's Receivables Turnover too high?
Egalet's current Receivables Turnover is 0.67. The Drug Manufacturers industry median Receivables Turnover is 5.06. Egalet's value of 0.67 is 86.8% below this industry median.
How does Egalet's Receivables Turnover compare to CPHI and TLGT?
Egalet's Receivables Turnover of 0.67 can be compared against companies in the Drug Manufacturers industry. The industry median Receivables Turnover is 5.06. Egalet's value of 0.67 is 86.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.06, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egalet's current Receivables Turnover of 0.67 is 86.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Egalet and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egalet's current Receivables Turnover is 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egalet stock overvalued right now?
Egalet (STU:EGP) has a current Receivables Turnover of 0.67. The current Receivables Turnover is 0.67 and 86.8% below the Drug Manufacturers industry median of 5.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Egalet (STU:EGP), the current Receivables Turnover is 0.67 as of Mar. 2020. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zyla Life Sciences is a U.S based company focused on marketing its portfolio of medicines for pain and inflammation. The products offered by the company include Sprix, Oxaydo, Vivlodex, Zorvolex, Tivorbex and Indocin Oral Suspension among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:EGP has been successfully added to your 
